Specifically, Vav1 synergizes with KRAS mutations to promote pancreatic cancer, while GEF–H1 facilitates hepatocellular carcinoma (HCC) metastasis by modulating RhoA‐dependent cytoskeletal changes. Here, VAV1 is linked to hepatocellular carcinoma.